Hydralazine-induced pulmonary-renal syndrome: a case report

Am J Ther. 2012 Jul;19(4):e136-8. doi: 10.1097/MJT.0b013e3181ed838c.

Abstract

Drug-induced lupus erythematosus differs in its manifestation from drug-induced vasculitis. The former is associated with characteristic symptoms that improve following discontinuation, whereas the latter is predominantly an antineutrophil cytoplasmic antibody (ANCA) positive small vessel vasculitis involving the kidneys, skin, and lungs. We present a case of advanced disease in an elderly Caucasian woman requiring corticosteroids, and immunosuppressive therapy, who was on hydralazine for >2 years.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Female
  • Glomerulonephritis / chemically induced*
  • Glomerulonephritis / physiopathology
  • Glucocorticoids / therapeutic use
  • Hemorrhage / chemically induced*
  • Hemorrhage / physiopathology
  • Humans
  • Hydralazine / adverse effects*
  • Hydralazine / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases / chemically induced*
  • Lung Diseases / physiopathology
  • Vasodilator Agents / adverse effects*
  • Vasodilator Agents / therapeutic use

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Vasodilator Agents
  • Hydralazine

Supplementary concepts

  • Rapidly progressive glomerulonephritis with pulmonary hemorrhage